ArticleMolecular and cellular biology2013
Expression of polycomb targets predicts breast cancer prognosis.
Article in Molecular and cellular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.Oncotarget · 2016Pooled it
- Biomedical literature mining: graph kernel-based learning for gene-gene interaction extraction.European journal of medical research · 2024Article
- Synthetic Reader-Actuators Targeted to Polycomb-Silenced Genes Block Triple-Negative Breast Cancer Proliferation and Invasion.GEN biotechnology · 2023Article
- Novel long non-coding RNAs associated with inflammation and macrophage activation in human.Scientific reports · 2023Article
- Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.The FEBS journal · 2021Article
- EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.Breast cancer (Tokyo, Japan) · 2021Article
- LncRNA HOTAIR regulates glucose transporter Glut1 expression and glucose uptake in macrophages during inflammation.Scientific reports · 2021Article
- Chromatin engineering offers an opportunity to advance epigenetic cancer therapy.Nature structural & molecular biology · 2019Article
- Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.Scientific reports · 2019Article
- LncRNA HOTAIR regulates lipopolysaccharide-induced cytokine expression and inflammatory response in macrophages.Scientific reports · 2018Article
- The synthetic histone-binding regulator protein PcTF activates interferon genes in breast cancer cells.BMC systems biology · 2018Article
- Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer.Scientific reports · 2018Article
- Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes.The Journal of biological chemistry · 2018Article
- Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers.International journal of molecular sciences · 2018Review
- Article
- A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.International journal of molecular sciences · 2017Review
- PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification.Bioinformatics (Oxford, England) · 2017Article
- Regulation of cancer epigenomes with a histone-binding synthetic transcription factor.NPJ genomic medicine · 2017Article
- Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?Molecular oncology · 2016Review
- EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.Diagnostic pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Global changes in the epigenome are increasingly being appreciated as key events in cancer progression. The pathogenic role of enhancer of zeste homolog 2 (EZH2) has been connected to its histone 3 lysine 27 (H3K27) methyltransferase activity and gene repression; however, little is known about relationship of changes in expression of EZH2 target genes to cancer characteristics and patient prognosis. Here we show that through expression analysis of genomic regions with H3K27 trimethylation (H3K27me3) and EZH2 binding, breast cancer patients can be stratified into good and poor prognostic groups independent of known cancer gene signatures. The EZH2-bound regions were downregulated in tumors characterized by aggressive behavior, high expression of cell cycle genes, and low expression of developmental and cell adhesion genes. Depletion of EZH2 in breast cancer cells significantly increased expression of the top altered genes, decreased proliferation, and improved cell adhesion, indicating a critical role played by EZH2 in determining the cancer phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.